Autobahn Therapeutics

In a lab off Campus Point Drive in San Diego, a small team is doing something the pharmaceutical industry has mostly stopped attempting: making new medicines for the brain and expecting them to work. Most of big pharma walked away from psychiatry a decade ago. Autobahn Therapeutics walked toward it.

Today the company is about 35 people, three drug programs, and one stubborn idea. Its lead molecule, elunetirom, just cleared a Phase 2 trial in bipolar depression and, in May 2026, picked up an FDA Fast Track designation. A second Phase 2, in major depressive disorder, is due to read out before the year is out. For a biotech this size, that is a lot of weather moving at once.

None of it is loud. There is no consumer app, no billboard, no founder doing the conference circuit in a hoodie. There is a thyroid hormone, a clever bit of chemistry, and a wager about where in the body a drug should be allowed to act.

The brain is a walled city

Here is the inconvenient fact that has wrecked countless drug programs: the brain protects itself. The blood-brain barrier is a wall of cells that keeps most molecules out, which is excellent news if you are a brain and terrible news if you are trying to treat one. Plenty of compounds work beautifully in a test tube and never make it past the gate.

The flip side is just as awkward. Some biology you would love to tap in the brain - the thyroid hormone pathway, for instance - is dangerous to crank up everywhere else in the body. Hit it system-wide and you risk the heart, the bones, the metabolism. So the useful target sits behind a wall, and the key, if you use it carelessly, breaks everything else in the house.

Depression research has lived inside this bind for decades. The field has reshuffled the same handful of mechanisms - serotonin, dopamine, norepinephrine - while patients who do not respond to those drugs simply ran out of options. The science was not missing. The delivery was.

Tune the address, not the target

Autobahn's origin is academic. The company was founded in 2017 on brain-targeting chemistry from the lab of Thomas Scanlan, a professor of physiology and pharmacology at Oregon Health & Science University, who remains a scientific co-founder and senior advisor. Scanlan spent years on a question most chemists treat as a footnote: not what a molecule binds, but where it ends up.

The bet that became a company: build small-molecule prodrugs that stay quiet in the body and switch on in the brain. Tune peripheral versus central exposure on purpose. Give each disease the distribution profile it actually needs. It is less glamorous than discovering a brand-new target and, if it works, considerably more useful - because the targets were never the problem.

Investors noticed. The company launched publicly in June 2020 with a $76 million Series B co-led by ARCH Venture Partners and Cowen Healthcare, with strategic checks from Bristol Myers Squibb, Biogen and Pfizer - three companies that compete fiercely and rarely agree on lunch, let alone a cap table.

A thyroid hormone, repurposed for mood

The lead drug is elunetirom, also known as ABX-002. On paper it is dry: an oral, once-daily, brain-penetrant CNS thyroid hormone receptor agonist. In plain terms, it slips into the brain and switches on genes tied to cellular energy, mitochondrial production, and the formation of new synaptic connections. The pitch is not to mask symptoms but to nudge the brain's own machinery back toward a healthier state.

Thyroid hormone and depression have a long, complicated history - clinicians have used thyroid augmentation for years, gingerly, because dosing the whole body is risky. Autobahn's version is built to act in the brain and largely leave the rest of you alone. That is the entire trick, and the boring engineering is the breakthrough.

The data that moved the needle

Bets are cheap. Trials are not. In its Phase 2 AMPLIFY-BD study, elunetirom added to standard care hit its primary endpoint and every key secondary one. Roughly three in four patients responded. Depression severity, measured on the Hamilton scale, fell by an average of 16.8 points over six weeks - the kind of effect that makes clinicians look twice rather than nod politely.

What makes the bipolar number interesting is the speed. The effect showed up fast, held over the six weeks, and arrived on top of whatever medication patients were already taking. Adjunctive is the unglamorous word that matters here - it means the drug has to work alongside existing treatment, not replace it, which is exactly how depression is treated in the real world. The FDA's Fast Track designation in May 2026 is a procedural nod, not an approval, but it signals the agency sees a serious unmet need and is willing to talk early and often.

The money tells a parallel story. Autobahn closed an oversubscribed $100 million Series C in July 2024, led by Newpath Partners with Canaan, Monograph Capital and Insight Partners joining - bringing total funding north of $200 million. Oversubscribed is investor-speak for "more people wanted in than there was room for," which, in a tight biotech market, is its own kind of clinical result.

Restoring hope, and meaning it

The stated mission - "restore hope for people affected by CNS disorders" - reads like every other biotech tagline until you remember the company hired a Head of People and Culture before it had an approved drug. The framing is regenerative: not numbing symptoms, but driving the brain back toward a healthier baseline using the body's own machinery.

It is a tall claim, and the company is careful with it. There is no approved product yet. Phase 2 wins are not Phase 3 wins, and the graveyard of CNS drugs is famously crowded with compounds that looked just as promising at this stage. But the through-line from Scanlan's chemistry to a Fast Track designation is unusually coherent for a field that often advances by accident.

Who benefits if the bet pays off is not abstract. Treatment-resistant depression and bipolar depression are among the hardest problems in psychiatry, and the people living with them have watched the industry cycle through the same mechanisms for a generation. A drug built to reach the brain cleanly, taken once a day by mouth, is not a moonshot pitch - it is a practical one. That practicality is the quietest and most credible thing about the company.

If the wall has a door

Here is the bigger prize hiding behind the depression headlines. If you can reliably tune where a drug acts - brain yes, body no - then a whole shelf of "validated but undruggable" biology comes back into play. Elunetirom is the proof of concept. The platform is the franchise. ABX-003 and ABX-101 are the company quietly saying: this was never a one-drug idea.

The next twelve months will test the thesis hard. The MDD readout lands this year. A pivotal bipolar trial is on deck. Either the brain-targeting bet holds across diseases, or it does not. That is the honest version - and Autobahn, to its credit, tells it that way too.

Back in that San Diego lab, the work looks the same as it did in 2017: chemistry, patience, and a hunch about geography. What has changed is the evidence. The walled city the industry mostly gave up on now has, at least, a candidate for a door - oral, once a day, and pointed straight at the brain. The road has a name. They are still driving it.